U.S. Water Utilities Stock News

NasdaqGS:PTCT
NasdaqGS:PTCTBiotechs

Is PTC Therapeutics (PTCT) Still Attractive After A 65% One-Year Share Price Jump

If you are trying to figure out whether PTC Therapeutics is genuinely good value or just riding biotech sentiment, it helps to line up the price against what the underlying business may be worth. The stock most recently closed at US$76.17, with returns of 0.7% over 7 days, a 2.0% decline over 30 days, a 0.7% decline year to date, and a 64.9% gain over 1 year, 65.6% over 3 years, and 35.1% over 5 years. Together, these figures can signal shifting views on its risk and reward profile. Recent...
NYSE:SO
NYSE:SOElectric Utilities

A Look At Southern Company’s Valuation After FORTUNE Names It Top Utility For 2024

Southern (SO) is back in focus after FORTUNE ranked it the No. 1 company in the electric and gas utilities industry, highlighting its reputation, financial soundness, and large-scale infrastructure investment plans. See our latest analysis for Southern. Despite the recent recognition and long term investment plans, Southern’s share price has been fairly muted, with a 1 month share price return of 1.3% and a 90 day share price decline of 8.7%, while the 1 year total shareholder return of 9.9%...
NYSE:ITGR
NYSE:ITGRMedical Equipment

Is Integer Holdings (ITGR) Attractive After Recent Medical Device Sector Interest?

If you are wondering whether Integer Holdings is priced attractively right now, the key question is how its current share price compares with what the business might be worth. The stock last closed at US$85.54, with returns of 0.3% over 7 days, 10.0% over 30 days, 11.4% year to date, 19.1% over 3 years and 11.2% over 5 years, set against a 40.3% decline over the last year. Recent news flow around Integer Holdings has focused on broader coverage of the medical device sector and investor...
NasdaqGS:ZS
NasdaqGS:ZSSoftware

Will Zscaler's (ZS) Agentic AI Security Push Redefine Its Zero Trust Leadership Narrative?

In January 2026, Zscaler, Inc. appointed Dr. Swamy Kocherlakota as Executive Vice President of Agentic AI Security Engineering to lead its response to emerging autonomous AI agent risks and expand the Zscaler Zero Trust Exchange™. This hire signals a push to address AI security at the architectural level, positioning Zscaler to serve developers and business leaders confronting complex new cyberthreats. We’ll now look at how this focus on securing autonomous AI agent workflows could shape...
NYSE:DX
NYSE:DXMortgage REITs

Dynex Capital Board Change Puts Focus On Valuation And Shareholder Dilution

Dynex Capital director Joy Palmer will not stand for re election to the Board at the upcoming Annual Meeting. Her departure will create a change in board composition and governance oversight at Dynex Capital, NYSE:DX. For investors watching Dynex Capital, NYSE:DX, the board update arrives with the stock at a share price of $14.44. Over the past year, the company shows a 34.0% return, and over 3 years a 47.7% return, with a 41.8% return over 5 years. In the shorter term, the stock shows a...
NYSE:WTRG
NYSE:WTRGWater Utilities

A Look At Essential Utilities (WTRG) Valuation After PFAS Funding And Solid Q3 Results

Why Aqua Pennsylvania’s PFAS funding matters for Essential Utilities Aqua Pennsylvania’s new US$16.9 million in PENNVEST support for PFAS treatment immediately puts Essential Utilities (WTRG) in the spotlight, linking regulatory compliance progress with the parent’s steady, regulated utility profile. See our latest analysis for Essential Utilities. Essential Utilities’ recent PFAS funding news comes after a mixed year in the market, with a 1-month share price return of 3.04% contrasting with...
NasdaqGS:OLED
NasdaqGS:OLEDSemiconductor

A Look At Universal Display (OLED) Valuation After Recent Share Price Weakness

Why Universal Display is Drawing Attention Now Universal Display (OLED) has been on some investors’ radar after a mixed return profile, with a small move over the past month but a negative total return over the past 3 months and year. See our latest analysis for Universal Display. At a share price of US$118.69, Universal Display’s recent moves have been relatively muted over the past month. However, the 90 day share price return of 19.26% decline and 1 year total shareholder return of 18.60%...
NYSE:JOE
NYSE:JOEReal Estate

Is It Too Late To Consider St. Joe (JOE) After A 36.8% One Year Gain

If you are wondering whether St. Joe at around US$64.79 is offering fair value or if the current price is getting ahead of itself, this article will walk you through what the numbers are indicating. The stock has returned 9.2% over the last 30 days and 36.8% over the past year, with a 1.1% decline over the last week and a year to date return of 8.3%. This naturally raises questions about how much of the story is already reflected in the price. Over the past year, St. Joe has continued to...
NasdaqGS:CVBF
NasdaqGS:CVBFBanks

CVB Financial (CVBF) Non Performing Loan Drop Tests Bearish Credit Narratives

CVB Financial (CVBF) just wrapped up FY 2025 with fourth quarter revenue of US$136.4 million and basic EPS of US$0.41, alongside quarterly net income of US$55.0 million. Over the last few quarters, the company has seen revenue move from US$126.8 million in Q4 2024 to US$136.4 million in Q4 2025, while quarterly EPS ranged from US$0.36 to US$0.41 over the same period. With a trailing twelve month net income of US$209.3 million and EPS of US$1.53, the latest release keeps the focus firmly on...
NasdaqGM:SMMT
NasdaqGM:SMMTBiotechs

Will Ivonescimab’s FDA Filing and GSK Combo Trial Redefine Summit Therapeutics’ (SMMT) Core Narrative?

Summit Therapeutics has entered into a clinical trial collaboration with GSK to test ivonescimab alongside GSK’s B7-H3-targeting ADC in multiple solid tumors, while also submitting a Biologics License Application to the FDA for ivonescimab plus chemotherapy in EGFR-mutated non-small cell lung cancer. Together, these steps highlight ivonescimab as the central asset in Summit’s pipeline, moving simultaneously toward potential US approval and broader oncology combinations with a major...
NasdaqGS:ARQT
NasdaqGS:ARQTBiotechs

Is It Time To Reassess Arcutis Biotherapeutics (ARQT) After A 96% One Year Rally?

If you are wondering whether Arcutis Biotherapeutics at US$26.65 is pricing in too much optimism or still leaving room on the table, the starting point is understanding what the market might already be expecting. The share price return sits at 1.1% over the last 7 days, with a 9.1% decline over 30 days, an 8.1% decline year to date, but a 96.0% return over 1 year and 65.5% over 3 years, which suggests sentiment around risk and potential has shifted over different time frames. Recent...
NasdaqGS:CHRD
NasdaqGS:CHRDOil and Gas

Chord Energy Enerplus Deal Tests Growth And Capital Return Story

Chord Energy (NasdaqGS:CHRD) has completed the acquisition of Enerplus, expanding its position in the Williston Basin. The deal adds to Chord Energy's inventory and is expected to improve its capital efficiency profile. This combination creates a larger, more concentrated Williston-focused operator with greater operational scale. Chord Energy, trading at $94.85, now reflects a business that is meaningfully larger in the Williston Basin through the Enerplus acquisition. The stock is up 3.2%...
NasdaqGM:PAYO
NasdaqGM:PAYODiversified Financial

Payoneer Expands Cross Border Platform With India Approval And Boundless Deal

Payoneer Global (NasdaqGM:PAYO) has received in-principle authorization from the Reserve Bank of India to operate as a Payment Aggregator for cross-border transactions. The company has also acquired Boundless, a workforce solutions provider with a focus on Europe. These developments expand Payoneer’s reach in India and Europe and broaden its cross-border payments and global workforce offerings. Payoneer Global, trading at $5.94, is drawing fresh attention as it pairs new regulatory progress...
NasdaqGS:ALKT
NasdaqGS:ALKTSoftware

Did New MANTL Wins And SDK Launch Just Shift Alkami Technology's (ALKT) Investment Narrative?

In recent weeks, Alkami Technology, Inc. announced multiple milestones for its MANTL platform, including new or expanded deployments at Harvard Federal Credit Union, Grow Financial Credit Union, and The Atlantic Federal Credit Union, alongside the rollout of its One-Click SDK Manager for developers. Together, these client wins and product enhancements highlight growing adoption of Alkami’s integrated digital banking and onboarding capabilities across account opening and lending, while...
NYSEAM:KULR
NYSEAM:KULRElectrical

A Look At KULR Technology Group’s Valuation After The New Caban Energy Supply Agreement

Why KULR’s New Caban Energy Deal Matters KULR Technology Group (KULR) recently announced a five year preferred battery supply agreement with Caban Energy. The agreement is expected to generate an estimated US$30 million in revenue starting in 2026 for critical infrastructure projects. See our latest analysis for KULR Technology Group. The Caban agreement comes as KULR’s 1 month share price return of 22.19% and year to date share price return of 35.94% contrast with a 1 year total shareholder...
NYSE:KEYS
NYSE:KEYSElectronic

Keysight Deepens EV Charging And Satellite 5G Role With Airbus Collaboration

Keysight Technologies (NYSE:KEYS) has introduced new EV charging test systems designed to handle high power, megawatt level charging. The company has also expanded its work with Airbus on the SpaceRAN demonstrator for advanced satellite based 5G network testing. Both developments aim to support emerging standards in EV charging and non terrestrial 5G connectivity. For investors watching NYSE:KEYS, these product moves come with the stock trading around $215.72 and a 1 year return of 24.6%...
NYSE:MC
NYSE:MCCapital Markets

Is Moelis (MC) Pricing In Too Much Optimism After Strong Multi Year Share Gains

If you are trying to work out whether Moelis at around US$76.91 is genuinely good value or just priced for perfection, you will want to look past the headline share price and into what different valuation methods actually say. The stock has had a mixed run, with a 1.1% decline over the last 7 days, a 9.3% gain over the last 30 days, an 8.0% return year to date, and returns of 2.8% over 1 year, 93.6% over 3 years, and 103.2% over 5 years. These figures can influence how much risk and upside...
NasdaqGS:ZG
NasdaqGS:ZGReal Estate

3 Stocks That May Be Undervalued By Up To 45.4% Based On Intrinsic Value Estimates

As the U.S. stock market navigates a volatile period marked by mixed performances across major indexes and record highs in safe-haven assets like gold and silver, investors are keenly observing opportunities that may arise from these fluctuations. In such an environment, identifying stocks that are potentially undervalued based on intrinsic value estimates can offer compelling prospects for those looking to capitalize on market inefficiencies.
NYSE:SOC
NYSE:SOCOil and Gas

3 High-Ownership Growth Companies Insiders Are Banking On

In a volatile week marked by mixed performances across major U.S. stock indexes, with the Dow Jones declining while the Nasdaq and S&P 500 posted modest gains, investors are increasingly seeking stability in companies with strong insider ownership. Such ownership can be a positive indicator of confidence in a company's growth potential, especially during uncertain market conditions.
NYSE:YSG
NYSE:YSGPersonal Products

Spotlight On Atea Pharmaceuticals And 2 Other Noteworthy Penny Stocks

Major stock indexes in the United States have experienced a mixed performance recently, reflecting ongoing market volatility and economic uncertainties. Amid these fluctuations, penny stocks remain an intriguing area for investors seeking opportunities in smaller or newer companies. Despite their vintage name, penny stocks can still offer significant value and growth potential when backed by strong financials. In this article, we'll explore three noteworthy examples of such stocks that may...